Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent in the local language prior to any study-mandated procedure.~* Body mass index from 18.0 to 30.0 kg/m2 (inclusive) at Screening.~* Normal renal function confirmed by creatinine clearance ≥ 80 mL/min using Cockroft-Gault formula at Screening.~Exclusion Criteria:~* Known hypersensitivity to cimetidine, lucerastat, or drugs of the same class, or any of their excipients.~* History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed).~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment period A & B (Type: EXPERIMENTAL): Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10).

Based on this trial design, predict the completion outcome and termination type (if applicable).